Sucroferric oxyhydroxide (trade name Velphoro) has been available since August 2014 for use by adults with chronic renal failure undergoing hemodialysis or peritoneal dialysis. The Institute for Quality and Efficiency in Health Care (IQWiG) has reviewed a dossier to determine whether the active ingredient in these cases provides patients with an additional benefit compared to the appropriate comparator therapies. There is additional benefit because no suitable data are available.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/zusatznutzen-von-sucroferric-oxyhydroxid-ist-nicht-belegt.6514.html?&et_cid=4&et_lid=%25208 [German]